New Afirma Xpression Atlas Clinical and Analytical Validation Data Published     READ MORE keyboard_arrow_right


WHY AFIRMA


Complex Landscape:

Thyroid nodule diagnosis is challenging



Arriving at an accurate diagnosis and treatment plan requires comprehensive information



ATA guidelines recommend more individualized care, as “…risk stratification is the cornerstone of individualized thyroid cancer management”2

Afirma enables individualized care and is supported by both ATA and NCCN guidelines



The Afirma Platform:

A unified and simple solution for all of your patients



Gain accurate and clinically actionable results from the first FNA



Comprehensive answers, confident decision-making, and personalized treatment



Afirma Genomic Sequencing Classifier:

Conclusively rule out surgery



Clinically validated



Real-world proven





Dependable Hürthle cell distinction


FOR HÜRTHLE CELL DOMINANT NODULES:



Trusted diagnostic certainty with Afirma GSC



Afirma Xpression Atlas (XA):

Confidently tailor treatment



Inform selection of surgical and therapeutic decisions

  • Afirma XA is informed by TCGA and extensive published literature to form a comprehensive panel* comprised of:


  • Afirma XA includes the most common and emerging variants and fusions associated with thyroid carcinoma, such as:




  • Afirma XA detects variants and fusions that may inform targeted therapy, such as:



*Levels of clinical relevance may vary based on specific variant/fusion identified by Afirma XA

For detailed literature reference of specific variants and fusions, refer to www.afirma.com/XA

Ordering Afirma Xpression Atlas is as simple as checking a box on your Afirma Test Requisition Form



Afirma GSC and Xpression Atlas:

Count on a simplified experience for your patients and your practice



Veracyte is committed to providing patient access regardless of financial situation

  • Covered by Medicare with no copayment12
  • Covered in-network by most commercial payers (over 260 million patients)12
  • The Veracyte Access Program supports both uninsured and commercially insured patients with financial need12




Get answers quickly12, reduce worry and wait

  • All-inclusive collection kit
  • Afirma GSC and XA on the same test requisition form




The Veracyte portal and mobile app

  • Easily receive, manage, and search electronic patient reports
  • Access the Veracyte portal at: portal.veracyte.com
  • Download the Veracyte app from your mobile app store
iOS App Google App




References: 1. Patel KN, et al. JAMA Surg. 2018. 2. Haugen BR, et al. Thyroid 2016. 3. Bongiovanni M, et al. Acta Cytol. 2012. 4. Shanik M, et al. ENDO 2018. 5. Ahmed S, et al. Endocr. Pract. 2018. 6. Endo M, et al. Thyroid 2018. 7. Harrell RM, et al. Endocr. Pract. 2018. 8. Livhits MJ, et al. Thyroid 2018. 9. Marqusee E, et al. Thyroid 2018. 10. San Martin VT, Nasr CE. Thyroid 2018. 11. Hao Y, et al. BMC Syst. Biol. 2019. 12. Data On File.

Contact us today
Monday to Friday, 5:30 AM – 5:00 PM (PST)
Phone: 1.888.923.4762
International: +1.650.243.6335
Fax: 650.243.6388
support@veracyte.com